Syndax Pharmaceuticals Inc — Director's Dealing 2021

Feb 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-02-08

Reporting Person: Morrison Briggs (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-08	Common Stock	M	35156.00	$7.20	Acquired	83492.00	Direct
2021-02-08	Common Stock	S	35156.00	$20.5485	Disposed	48336.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-08	Stock Options (Right to buy)	$7.20	M	35156.00	Disposed	2025-06-30	Common Stock (35156.00)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 1,161,507 options to purchase shares of common stock that are vested and immediately exercisable and a total of 518,334 options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $20.00 to $20.93.

F3: This option is fully vested.